Medannex team grows to 12 employees, as preparations for First-in-Human study gather pace

05 January 2021

Despite the challenges posed by the COVID-19 pandemic, Medannex completed its planned expansion to 12 employees over the course of 2020.

With new in-house expertise in several key areas, including clinical project management and regulatory affairs, the company is well-positioned to initiate a First-in-Human clinical study later this year.

The company looks forward to generating the first clinical data on its lead antibody therapy, MDX-124, which has shown significant anti-cancer activity in multiple non-clinical models.